Regina Vasiliou
About Regina Vasiliou
Regina Vasiliou is the Senior Business Unit Director of Innovative Medicines at Bristol Myers Squibb in Rome, Italy. She has extensive experience in the pharmaceutical industry, having held various leadership roles at Novartis Oncology.
Title
Regina Vasiliou holds the position of Senior Business Unit Director Innovative Medicines at Bristol Myers Squibb. Her role involves overseeing the business unit’s strategic initiatives and driving forward its objectives in alignment with the company's goals.
Current Position at Bristol Myers Squibb
Regina Vasiliou is currently based in Rome, Italy, working as the Senior Business Unit Director Innovative Medicines for Bristol Myers Squibb. In this role, she reports directly to the General Manager for Italy, and is a member of the Country Leadership Team. She is responsible for therapeutic areas such as Cardiovascular and Immunoscience, including Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, and Ulcerative Colitis.
Previous Roles at Novartis Oncology
Regina Vasiliou has an extensive background in various positions at Novartis Oncology. From 2017 to 2020, she served as VP & Disease Area Lead MPNs/GVHD (JAKAVI) in the Basel Area, Switzerland. Prior to that, she was Head Solid & Rare Tumors Franchise from 2014 to 2017 in Origgio, Italy. Between 2011 and 2014, she worked as General Manager in Dublin, Ireland, and from 2008 to 2011, she held the position of Head Market Access CEC (South & Eastern Europe). Earlier, she was Head Oncology Business Unit in Nicosia, Cyprus, from 2006 to 2008, Product Manager from 2005 to 2006, and Medical Representative from 2004 to 2005.
Education and Qualifications
Regina Vasiliou earned her Doctor of Pharmacy (Pharm.D.) degree from Ethnikon kai Kapodistriakon Panepistimion Athinon, where she studied Pharmacy from 1999 to 2004. Prior to that, she attended Pagkyprio Gymnasio from 1996 to 1999.
Collaborations and Strategic Roles
Regina Vasiliou serves as the Co-Chair of the Eliquis Alliance with Pfizer, focusing on cardiovascular therapeutic areas. She is also a member of the Major Markets BU Directors Board, where she contributes to commercial strategies at Major Markets and Worldwide levels. In her role at Bristol Myers Squibb, she actively participates in defining and implementing commercial strategies to ensure alignment with the company’s strategic objectives for the Business Unit.